<DOC>
	<DOC>NCT01173471</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of systemically administered AZD4017, compared with placebo, over a 28-day period in patients with raised intra-ocular pressure (IOP).</brief_summary>
	<brief_title>A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure</brief_title>
	<detailed_description />
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Must have a diagnosis of intraocular hypertension (raised IOP), or primary openangle glaucoma (POAG), with IOP &gt;20 mmHg and ≤36 mmHg in the study eye, and is currently prescribed a stable dose of a single antiglaucoma medication that began at least 30 days prior to the screening visit; OR Must have a diagnosis of intraocular hypertension (raised IOP), defined as an IOP ≥22 mmHg and ≤36 mmHg in the study eye while not on antiglaucoma medication Male patients must be willing to use barrier contraception with spermicide, ie, condoms, from the day of first dosing until 3 months after dosing with IP Placebo treatment for duration of the study must not be considered detrimental to the patient Have uncontrolled intraocular hypertension (&gt;36 mmHg) Have experienced a significant visual field loss or showed evidence of progressive visual field loss within the last year (as defined by &gt;1 dB/yr average loss or vision threatening new defect) Have had severe eye trauma at any time</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Raised intraocular pressure</keyword>
</DOC>